Your browser doesn't support javascript.
loading
Resource requirements to accelerate clinical applications of next generation sequencing and radiomics: Workshop commentary and review.
Harris, Lyndsay; Shankar, Lalitha K; Hildebrandt, Claire; Rubinstein, Wendy S; Langlais, Kristofor; Rodriguez, Henry; Berger, Adam; Freymann, John; Huang, Erich P; Williams, P Mickey; Claude Zenklusen, Jean; Ochs, Robert; Tezak, Zivana; Sahiner, Berkman.
Afiliação
  • Harris L; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Shankar LK; Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Hildebrandt C; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rubinstein WS; Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Langlais K; Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rodriguez H; Office of In Vitro Diagnostics (OHT7), Office of Product Evaluation and Quality, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Berger A; Office of Cancer Clinical Proteomics Research, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Freymann J; Division of Clinical and Healthcare Research Policy, Office of Science Policy, National Institutes of Health, Bethesda, MD, USA.
  • Huang EP; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Williams PM; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Claude Zenklusen J; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Ochs R; The Cancer Genome Atlas, Center for Cancer Genomics, Office of the Director, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Tezak Z; Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Sahiner B; Office of Health Technology 8, Office of Product Evaluation and Quality, Center for Devices and Radiological Health, U.S. Food and Drug Administration, Silver Spring, MD, USA.
J Natl Cancer Inst ; 2024 Jun 12.
Article em En | MEDLINE | ID: mdl-38867688
ABSTRACT
The National Institutes of Health (NIH)/U.S. Food and Drug Administration (FDA) Joint Leadership Council Next-Generation Sequencing (NGS) and Radiomics Working Group (NGS&R WG) was formed by the NIH/FDA Joint Leadership Council to promote the development and validation of innovative NGS tests, radiomic tools, and associated data analysis and interpretation enhanced by artificial intelligence (AI) and machine-learning (ML) technologies. A two-day workshop was held on September 29-30, 2021 to convene members of the scientific community to discuss how to overcome the "ground truth" gap that has frequently been acknowledged as one of the limiting factors impeding high-quality research, development, validation, and regulatory science in these fields. This report provides a summary of the resource gaps identified by the WG and attendees, highlights existing resources and the ways they can potentially be leveraged to accelerate growth in these fields, and presents opportunities to support NGS and radiomic tool development and validation using technologies such as AI and ML.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article